28622 Federal Register / Vol. 75, No. 98 / Friday, May 21, 2010 / Notices 

Dated: May 13, 2010. 

Maryam I. Daneshvar, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2010–12182 Filed 5–20–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Conducting 

Public Health Research in Kenya 

(U01)(Panel A), Funding Opportunity 

Announcement (FOA) GH10–003, Initial 

Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

TIME AND DATE: 1 p.m.–5 p.m., June 29, 

2010 (Closed). 

PLACE: Teleconference. 

STATUS: The meeting will be closed to 

the public in accordance with 

provisions set forth in Section 552b(c) 

(4) and (6), Title 5 U.S.C., and the 

Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92– 

463. 

MATTERS TO BE DISCUSSED: The meeting 

will include the initial review, 

discussion, and evaluation of 

applications received in response to 

‘‘Conducting Public Health Research in 

Kenya (U01)(Panel A),’’ FOA GH10–003. 

CONTACT PERSON FOR MORE INFORMATION: 

Susan Stanton, D.D.S., Scientific Review 

Officer, CDC, 1600 Clifton Road, NE., 

Mailstop D74, Atlanta, GA 30333, 

Telephone: (404) 639–4640. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: May 6, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–12174 Filed 5–20–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0247] 

FDA Transparency Initiative: Draft 

Proposals for Public Comment 

Regarding Disclosure Policies of the 

U.S. Food and Drug Administration; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability; request 

for comments. 

SUMMARY: As part of the second phase 

of the Transparency Initiative, the Food 

and Drug Administration (FDA) is 

announcing the availability of a report 

entitled ‘‘FDA Transparency Initiative: 

Draft Proposals for Public Comment 

Regarding Disclosure Policies of the 

U.S. Food and Drug Administration.’’ 

The report includes 21 draft proposals 

about expanding disclosure of 

information by the agency while 

maintaining confidentiality of trade 

secrets and individually identifiable 

patient information. FDA is seeking 

public comment on the draft proposals, 

as well as on which draft proposals 

should be given priority. Some of the 

draft proposals may require extensive 

resources to implement, and some may 

require changes to regulations or 

legislation. 

DATES: Submit either electronic or 

written comments by July 20, 2010. 

ADDRESSES: Submit electronic 

comments to http://www.regulations.gov 

or on the FDA Web site, www.fda.gov/ 

transparency. Submit written comments 

to the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets at the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: Afia 

Asamoah, Office of the Commissioner, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg 1, rm. 2220, 

Silver Spring, MD 20993, 301–796– 

4625, FAX: 301–847–3531, e-mail: 

Afia.Asamoah@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Every day, the U.S. Food and Drug 

Administration (FDA) makes important 

health and safety decisions about foods, 

drugs, medical devices, cosmetics, and 

other widely used consumer products. 

Transparency in FDA’s activities and 

decisionmaking allows the public to 

better understand the agency’s 

decisions, increasing credibility and 

promoting accountability. Transparency 

helps the agency to more effectively 

protect and promote the public health. 

In January 2009, President Obama 

issued a memorandum on Transparency 

and Open Government calling for an 

‘‘unprecedented level of openness in 

Government’’ and directing the Director 

of the Office of Management and Budget 

(OMB) to issue an Open Government 

Directive instructing executive 

departments and agencies to take 

specific actions to implement the 

principles of transparent, collaborative, 

and participatory government. The 

Open Government Directive was issued 

in December. Under the leadership of 

Secretary Kathleen Sebelius, the U.S. 

Department of Health and Human 

Services has also prioritized 

transparency and openness. In June 

2009, FDA Commissioner Dr. Margaret 

Hamburg launched FDA’s Transparency 

Initiative to implement these efforts at 

FDA. 

The initiative is overseen by a Task 

Force representing key leaders of FDA. 

The internal task force is chaired by the 

Principal Deputy Commissioner of the 

FDA and includes five of the agency’s 

center directors, the Chief Counsel, the 

Associate Commissioner of Regulatory 

Affairs, and the Chief Scientist. The 

Task Force is charged with submitting a 

written report to the Commissioner on 

the Task Force’s findings and 

recommendations. 

Over the last 11 months, the Task 

Force has held two public meetings, 

launched an online blog (http:// 

fdatransparencyblog.fda.gov/), and 

opened a docket. The online blog and 

the docket have received over 1,500 

comments. 

The Task Force is proceeding with the 

Transparency Initiative in three phases: 

• Phase I: FDA Basics 

• Phase II: Public Disclosure 

• Phase III: Transparency to 

Regulated Industry 

Phase I is intended to provide the 

public with basic information about 

FDA and how the agency does its work. 

This phase was unveiled in early 

January 2010 with the launch of a webbased resource called FDA Basics 

(www.fda.gov/fdabasics). The resource 

now includes (1) 126 questions and 

answers about FDA and the products 

that the agency regulates, (2) 9 short 

videos that explain various FDA 

activities, and (3) 10 conversations with 

FDA officials about the work of their 

Offices. Each month, senior officials 

from FDA product centers and offices 

host online sessions about a specific 

topic and answer questions from the 


emcdonald on DSK2BSOYB1PROD with NOTICES